Literature DB >> 26380628

Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma.

Chase Doyle.   

Abstract

Entities:  

Year:  2015        PMID： 26380628      PMCID： PMC4570074     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  5 in total

Review 1.  Basis for molecular diagnostics and immunotherapy for esophageal cancer.

Authors:  Joe Abdo; Devendra K Agrawal; Sumeet K Mittal
Journal:  Expert Rev Anticancer Ther       Date:  2016-11-23       Impact factor: 4.512

2.  Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.

Authors:  Liangliang Meng; Xiaoxi He; Xiao Zhang; Xiaobo Zhang; Yingtian Wei; Bin Wu; Wei Li; Jing Li; Yueyong Xiao
Journal:  PLoS One       Date:  2020-10-08       Impact factor: 3.240

3.  Abscopal Effect of Frozen Autograft Reconstruction Combined with an Immune Checkpoint Inhibitor Analyzed Using a Metastatic Bone Tumor Model.

Authors:  Noritaka Yonezawa; Hideki Murakami; Satoru Demura; Satoshi Kato; Shinji Miwa; Katsuhito Yoshioka; Kazuya Shinmura; Noriaki Yokogawa; Takaki Shimizu; Norihiro Oku; Ryo Kitagawa; Makoto Handa; Ryohei Annen; Yuki Kurokawa; Kazumi Fushimi; Eishiro Mizukoshi; Hiroyuki Tsuchiya
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

Review 4.  Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers.

Authors:  Joe Abdo; David L Cornell; Sumeet K Mittal; Devendra K Agrawal
Journal:  Front Oncol       Date:  2018-03-28       Impact factor: 6.244

Review 5.  Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).

Authors:  Young Kwang Chae; Ayush Arya; Wade Iams; Marcelo R Cruz; Sunandana Chandra; Jaehyuk Choi; Francis Giles
Journal:  J Immunother Cancer       Date:  2018-05-16       Impact factor: 13.751
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.